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ABSTRACT 
 
Aims: To assess the prevalence of A. xylosoxidans isolated from non-respiratory tract samples 
from adult inpatients and outpatients and the antibiotic resistance levels at a tertiary-care teaching 
hospital in Szeged, Hungary retrospectively, during a 10-year study period. 
Study Design: Retrospective microbiological study. 
Place and Duration of Study: 1
st
 of January 2008 - 31
st
 of December 2017 at the University of 
Szeged, which is affiliated with the Albert Szent-Györgyi Clinical Center, a primary- and tertiary-
care teaching hospital in the Southern Great Plain of Hungary. 
Methodology: Data collection was performed electronically. Antimicrobial susceptibility testing 
(AST) was performed using disk diffusion method and when appropriate, E-tests on Mueller–Hinton 
agar plates.  
Results: During the 10-year study period, a total of 68 individual A. xylosoxidans isolates were 
identified (6.8±3.6/year, range: 0-11 isolates). The frequency of isolation in the first half of the study 
period (2008-2017) was n=22, while in 2013-2017, this number was n=46. The majority of isolates 
(51 out of 68) were from inpatient departments. 32 out of 68 patients were female (female-to-male 
ratio: 0.89). The susceptibilities of the respective A. xylosoxidans isolates (n=68) were the 
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following: high levels of susceptibility for imipenem and meropenem (n=63; 92.6%), and 
moxifloxacin (n=55; 80.9%), while higher rates of resistance were detected for 
sulfamethoxazole/trimethoprim (susceptible: n=36; 52.9%), ciprofloxacin (susceptible: n=40; 
58.8%) and almost all isolates were resistant to ceftazidime (susceptible: n=3; 4.4%) and cefepime 
(n=2; 2.9%). 
Conclusion: The existing literature on Achromobacter infections in the context of non-respiratory 
human infections is scarce, as the incidence of these pathogens in clinically-relevant syndromes in 
low. The developments in diagnostic technologies in routine clinical microbiology will probably lead 
to a shift in the isolation frequency of these bacteria in the future. 
 
 
Keywords: Achromobacter xylosoxidans; non-fermenting; Gram-negative; epidemiology; 
immunocompromised; retrospective; clinical microbiology; medicine. 
 
ABBREVIATIONS 
 
COL : Colistin;  
CZD : Ceftazidime;  
FEP : Cefepime; 
IMP : Imipenem; 
MER : Meropenem;  
CIP : Ciprofloxacin;  
MOX : Moxifloxacin; 
SXT : Sulfamethoxazole/ 
Trimethoprim; 
CF : Cystic Fibrosis; 
 MDR : Multidrug-Resistant; 
XDR : Extensively Drug Resistant; 
PDR : Pandrug Resistant; 
EUCAST : European Committee for Anti-
microbial Susceptibility 
Testing; 
US : United States; 
HIV : Human Immunodeficiency 
Virus;  
ICU : intensive Care Unit; 
CFU : Colony-Forming Units; 
MALDI-TOF MS : Matrix-Assisted Laser 
Desorption-Ionization Time-
of-Flight Mass Spectrometry; 
 
1. INTRODUCTION  
 
The genus Achromobacter includes lactose-non-
fermenting Gram-negative bacteria that are 
aerobic, motile (with peritrichous flagella), 
oxidase and catalase-positive [1]. Taxonomically, 
these bacteria are the members of the 
Alcaligenaceae family of the Burkholderiales 
order; based on their genome sequences, these 
bacteria are most similar to Bordetella species 
[2]. In fact, until recently, the genus 
Achromobacter was specified into the 
Alcaligenes genus [3]. The members of the 
genus are ubiquitous, their isolation has been 
reported from soil samples, water reservoirs and 
from plants [4]. From the context of clinical 
samples, A. xylosoxidans is the most frequently 
isolated species; the isolation of this pathogen 
has been described from blood [5], stool [6], 
urine [7], cerebrospinal fluid [8], peritoneal fluid 
[9], sputum [10], ear discharge [11], abscesses 
[12], bone and joint samples [13] and central 
venous catheters [10]. However, the most clinical 
data to date have been collected on A. 
xylosoxidans pneumonia in cystic fibrosis (CF) 
patients [14,15]. The prevalence of this pathogen 
in the sputum of CF-patients is estimated to be 
around 2-25%, and co-infection or co-isolation 
with Pseudomonas aeruginosa is very common 
[16]. In lung transplant patients with CF, it was 
observed that the pan-resistant (PDR) A. 
xylosoxidans was present before transplantation, 
and that this PDR A. xylosoxidans recurred in 
one-third of patients after transplantation [17]. 
However, colonization with A. xylosoxidans did 
not correlate with post-transplant survival and 
should not be considered as a reason for 
transplant rejection in the US, but the decrease 
in lung function after transplantation showed 
correlation with the presence of this bacterium 
[18].  
 
Most of the reported cases of non-CF A. 
xylosoxidans infections are nosocomial infections 
in immunocompromised hosts: the source of the 
infection may be the indwelling catheters, 
endotracheal tubes or other invasive medical 
devices [19]. In addition, the gastrointestinal tract 
has been suspected as a source of invasive 
infection, where the increased permeability of the 
mucosal barrier may lead to disseminated 
infections, such as sepsis and meningitis [20]. 
The most numerous cases in adults have been 
reported in patients with malignancies, HIV-
infection, neutropenia, bone marrow transplant, 
IgM-deficiency and high-dose corticosteroid 
therapy, while pre-term delivery is an 
independent risk factor in infants [4-21]. 
Therefore, Achromobacter spp. are recognized 
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as emerging pathogens that can cause infections 
in patients with impaired immune system and are 
well-known nosocomial pathogens, especially in 
the intensive care units (ICUs) [10]. However, 
clinicians often are uninformed about the 
microbiology and clinical relevance of these 
bacteria and dismiss them as contaminants.  
 
The epidemiology and antibiotic susceptibility-
patterns of pathogens vary greatly by region; 
therefore, the assessment of local data is 
essential to evaluate trends over time and to 
reflect on the national situation compared to 
international data. With this in mind, the aim of 
this study was to assess the prevalence of A. 
xylosoxidans isolated from non-respiratory tract 
samples from adult inpatients and outpatients 
and the antibiotic resistance levels at a tertiary-
care teaching hospital in Szeged, Hungary 
retrospectively, during a 10-year study period. 
 
2. METHODOLOGY  
 
2.1 Location and Population of the Study, 
Data Collection 
 
During our study, the laboratory information 
system of the Institute of Clinical Microbiology 
(University of Szeged) was searched for samples 
positive for A. xylosoxidans, corresponding to the 
time period between 2008.01.01.–2017.12.31 
(10 years). The Institute is the primary 
microbiological diagnostic laboratory of the Albert 
Szent-Györgyi Clinical Center, providing medical 
care for a population of around 600,000 people, 
based on the most recent census data [22]. Data 
collection was performed electronically, based on 
the following criteria: samples with significant 
colony counts for A. xylosoxidans (>10
5
 CFU/mL 
for urine samples, while >10
3
 in case of other 
types of clinically-relevant samples; however, this 
was subject to interpretation by the senior clinical 
microbiologists, based on the information 
provided on the clinical request forms for the 
microbiological analysis and international 
guidelines) [22]. Respiratory samples were 
excluded from this analysis. Only the first isolate 
per patient was included in the study; however, 
isolates with different antibiotic-susceptibility 
patterns from the same patient were considered 
as different individual isolates. To evaluate the 
demographic characteristics of these infections, 
patient data was also collected, which was 
limited to sex, age at sample submission, and 
inpatient/outpatient status of patients over 18 
years of age. The immune status of the patients 
or their underlying illnesses were not known 
during the study. 
2.2 Sample Processing and Identification 
 
The processing of relevant samples arriving to 
the Institute of Clinical Microbiology was carried 
out according to guidelines in routine clinical 
bacteriology. Between 2008–2012, the BD 
Bactec (Beckton Dickinson, Franklin Lakes, NJ, 
USA) detection system was employed for the 
incubation of blood culture bottles, whilst from 
2013 onwards, the BacT/ALERT 3D (bioMérieux, 
Marcy-l’Étoile, France) detection system was 
used. Blood culture bottles were incubated for 5 
days (21 days, if endocarditis was suspected) in 
the abovementioned detection systems. The 
processing of urine samples was as follows: 10 
µL of each un-centrifuged urine sample was 
cultured on UriSelect chromogenic agar plates 
(Bio-Rad, Berkeley, CA, USA) with a calibrated 
loop, according to the manufacturer’s instructions 
and incubated at 37°C for 24–48 h, aerobically. 
The workup of faecal samples was performed on 
the appropriate non-selective and selective 
media, relevant to the isolation of diarrheal 
pathogens. If the relevant pathogens presented 
in significant colony count, the plates were 
passed on for further processing [23].  
 
Between 2008–2012, presumptive phenotypic 
(biochemical reaction-based) methods and 
VITEK 2 ID (bioMérieux, Marcy-l’Étoile, France) 
were used for bacterial identification, while after 
2013, this was complemented by matrix-assisted 
laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS; Bruker Daltonik 
Gmbh. Gr., Bremen, Germany). Bacterial cells 
were transferred to a stainless-steel target. An 
on-target extraction was performed by adding 1 
µl of 70% formic acid prior to the matrix. After 
drying at ambient temperature, the cells were 
covered with 1 µl matrix (α-cyano-4-hydroxy 
cinnamic acid in 50% acetonitrile/2.5% trifluoro-
acetic acid). Mass spectrometry was performed 
by the Microflex MALDI Biotyper (Bruker 
Daltonics, Bremen, Germany) in positive linear 
mode across the m/z range of 2 to 20 kDa; for 
each spectrum, 240 laser shots at 60 Hz in 
groups of 40 shots per sampling area were 
collected. The MALDI Biotyper RTC 3.1 software 
(Bruker Daltonics) and the MALDI Biotyper 
Library 3.1 were used for spectrum analysis [24]. 
 
2.3 Antimicrobial Susceptibility Testing 
(AST) 
 
Antimicrobial susceptibility testing was performed 
using the Kirby–Bauer disk diffusion method and 
when appropriate, E-test (Liofilchem, Abruzzo, 
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Italy) on Mueller–Hinton agar (MHA) plates. The 
interpretation of the results was based on 
EUCAST breakpoints for Pseudomonas spp. and 
Acinetobacter spp. (when relevant). The 
following antibiotics were tested: 
piperacillin/tazobactam (TZP), ceftazidime 
(CZD), cefepime (FEP), imipenem (IMP), 
meropenem (MER), ciprofloxacin (CIP), 
moxifloxacin (MOX) and sulfamethoxazole/ 
trimethoprim (SXT). Colistin (COL) susceptibility 
was performed using the broth microdilution 
method in a cation-adjusted Mueller-Hinton broth 
(MERLIN Diagnostik) [25]. Colistin susceptibility 
testing was not routinely performed, only per 
request of the clinicians. During data analysis, 
intermediately-susceptible results were grouped 
with and reported as resistant. Classification of 
the isolates as a multidrug resistant (MDR) or 
extensively drug resistant (XDR) was based on 
the EUCAST Expert Rules [26]. Staphylococcus 
aureus ATCC 29213, Enterococcus faecalis 
ATCC 29212, Proteus mirabilis ATCC 35659, 
Escherichia coli ATCC 25922, Klebsiella 
pneumoniae ATCC 700603 and P. aeruginosa 
ATCC 27853 were used as quality control 
strains. 
 
2.4 Statistical Analysis 
 
Descriptive statistical analysis (including means 
or medians with ranges and percentages to 
characterize data) was performed using 
Microsoft Excel 2013 (Redmond, WA, Microsoft 
Corp.). 
 
3. RESULTS AND DISCUSSION 
 
3.1 Epidemiology of A. xylosoxidans 
 
During the 10-year study period, a total of 68 
individual A. xylosoxidans isolates were identified 
(6.8±3.6/year, range: 0-11 isolates; highest in 
2016, lowest in 2009 and 2011) from non-
respiratory tract samples. The frequency of 
isolation in the first half of the study period (2008-
2017) was n=22, while in 2013-2017, this 
number was n=46. It must be noted that n=12 
non-xylosoxidans Achromobacter species have 
also been isolated, however, these were 
excluded from this data analysis. 
 
 3.2 Demographic Characteristics  
 
The majority of isolates (51 out of 68) were from 
inpatient departments, namely the Intensive Care 
Department (n=23), Department of Traumatology 
(n=14), Department of Internal Medicine (n=6), 
Department of Immunology and Allergology 
(n=5) and Department of Neurology (n=3); the 
rest n=17 of the isolates came from various 
outpatient clinics. A. xylosoxidans was isolated 
from the following samples types: urine 
(midstream and catheterized): n=26, blood 
cultures: n=17, central venous catheters: n=8, 
faeces: n=7, biopsy samples: n=6, puncture 
samples: n=4, respectively. No dominance 
regarding the distribution of patients were 
observed towards either sexes: 32 out of 68 
patients were female (female-to-male ratio: 0.89); 
the age distribution of patients was the following: 
18-35 years: n=9, 36-59 years: n=15 and 60 
years or older: n=44. 
 
3.3 Antimicrobial Susceptibility 
 
The susceptibilities of the respective A. 
xylosoxidans isolates (n=68) were the following: 
high levels of susceptibility for IMP and MER 
(n=63; 92.6%), and MOX (n=55; 80.9%), while 
higher rates of resistance were detected for SXT 
(susceptible: n=36; 52.9%), CIP (susceptible: 
n=40; 58.8%) and almost all isolates were 
resistant to CZD (susceptible: n=3; 4.4%) and 
FEP (n=2; 2.9%). COL susceptibility was 
performed in n=10 cases, all isolates were 
susceptible. Based on AST results, n=4 (5.9%) 
could be considered as MDR, while no XDR 
isolates were detected. 
 
3.4 Discussion 
 
The present study reports on the epidemiological 
features of A. xylosoxidans infections at a 
tertiary-care hospital in Hungary over a period of 
a decade (2008-2017). Although the relevance of 
this pathogen is emerging and its isolation and 
identification is becoming more frequent, little is 
known regarding the virulence characteristics of 
Achromobacter, especially the ones concerning 
its ability to adhere, colonize and subsequently 
cause infections in vivo [26,27]. The following 
virulence determinants have been identified in 
the genus: Flagella, lipopolysaccharide (LPS), 
other membrane-associated structures, 
phospholipase C, various proteases, cellulose, a 
type-3 secretion system (T3SS); these have all 
been noted to have roles in the inflammatory 
reaction caused by this bacteria in the airways, 
however, their roles in invasive infections are not 
yet understood [26-28]. In addition, the bacteria 
possess the ability to denitrify, thus, allowing for 
their persistence and survival in hypoxic or 
anaerobic environments [2-4]. The production of 
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biofilm is another significant factor in the 
pathogenicity and survival of A. xylosoxidans in 
both respiratory infections and catheter-
associated infections [29]. The reported mortality 
rate in invasive Achromobacter infections is 
around 2% for bacteremia, while this may reach 
80% in case of neonatal sepsis [4-21,30].  
 
Similarly to other non-fermenting Gram-negative 
bacteria, Achromobacter species have a plethora 
of intrinsic resistance mechanisms: penicillins, 1-
2
nd
 generation cephalosporins, chloramphenicol, 
macrolides and aminoglycosides [4-13,17,31,32]. 
Fluoroquinolones are usually considered as the 
part of a combination regimen (not as 
monotherapy) with carbapenems, therefore IMP, 
MER, TZP and SXT are the drugs of choice in 
these infections, preferably in combination. COL 
remains a viable alternative in case of extensive 
resistance, however, there are limited clinical 
experiences with these drugs against 
Achromobacter species [32]. In addition, due to 
the genetic plasticity of these microorganisms, 
they may also facilitate horizontal gene transfer 
between bacteria, promoting the spread of 
antimicrobial resistance. The over-expression of 
bacterial efflux pumps is another significant 
resistance mechanism in this pathogen, mainly 
affecting susceptibilities for the fluoroquinolones. 
Resistance against β-lactams has also been 
noted, both in the form of intrinsic (blaOXA-144-like, 
blaOXA-2, blaOXA-243), inducible (AmpC enzymes) 
and plasmid-mediated (blaIMP) β-lactamases, and 
the effects of efflux pumps were also associated 
with β-lactam resistance [10]. In these cases, the 
therapeutic armamentarium for these infections 
narrows significantly [33,34].  
  
4. CONCLUSION 
 
The existing literature on Achromobacter 
infections in the context of non-respiratory 
human infections is scarce, as the incidence of 
these pathogens in clinically-relevant syndromes 
in low. It should be noted, that the difficulty in the 
adequate identification (especially in low-
resource settings) may be partly blamed for the 
infrequent characterization of these bacteria as 
significant pathogens. Nevertheless, the 
developments in diagnostic technologies in 
routine clinical microbiology (e.g., MALDI-TOF 
MS) will probably lead to a shift in the isolation 
frequency of these bacteria in the future. Due to 
these technical developments in routine 
microbiology, the prevalence of bacterial species 
that were previously considered as rare will most 
probably increase, which is reflected in the 
increase in the interest towards these bacteria in 
the literature and our present report.  
 
5. LIMITATIONS 
 
Some limitations of this study should be noted: 
the retrospective design and the inability to 
access the medical records of the individual 
patients affected by these infections hindered the 
authors from assessing the correlation of the 
relevant risk factors and underlying pathologies 
with the isolation of A. xylosoxidans. The 
selection bias is a characteristic of such 
epidemiological studies, as most of these reports 
are originated from tertiary-care centers, 
corresponding to patients with more severe 
conditions or underlying illnesses. Lastly, the 
molecular characterization of resistance 
determinants in the mentioned isolates was not 
performed, non-susceptibility was characterized 
by phenotypic methods only. In future studies, a 
prospective study design and the comprehensive 
characterization of the medical history and 
laboratory parameters would aid the definition of 
the real pathogenic role of these bacteria.  
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